Melanoma Diagnostics Sells Genetic Marker Technology

Altadena-based Melanoma Diagnostics, a developer of technology for the diagnosis and prognosis of malignant melanoma using genetic markers, is in a deal to sell its technology to Myriad Genetics, a publicly traded provider of molecular diagnostics products. Financial terms of the deal were not disclosed.Myriad said it will gain the right to commercialize all tests derived from Melanoma Diagnostics' technology, in exchange for both upfront fees and contingent payments. Melanoma Diagnostics is headed by Dr. Kevin Scanlon, who is known in the technology community for his work with both the Pasadena Angels and the Tech Coast Angels.